Renal cell carcinoma: which criteria to define antiangiogenic treatment failure? A case report.

Date publication

mars 2010

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LANG Hervé

Tous les auteurs :
Lang H, Lassau N, Thibault F, Delva R, Pignot G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20493439

Résumé

Failure criteria of antiangiogenic treatment that must make envisage a change of molecule are still difficult to define. Concerning the evaluation of the response, if the RECIST criteria seem to be limited, several other tools of evaluation (clinical, radiological or biological tools) can be interesting. It is the case of contrast-enhanced ultra-sonography, but a precise definition of functional parameters should be defined and a standardization of the technique is necessary. Side effects do not translate necessarily a treatment failure. They must be estimated by taking into account the frequency of some of symptoms. Asthenia is noticed in more than 50 % of the patients; it is however necessary to exclude another aetiology, in particular iatrogenic hypothyroidism. (C) 2010 Published by Elsevier Masson SAS.

Référence

Prog Urol. 2010 Mar;20 Suppl 1:S23-6